A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Parkinson Disease
Interventions
DRUG

Vutiglabridin

Once-daily oral administration

DRUG

Placebo

Once-daily oral administration

Trial Locations (9)

11765

RECRUITING

The Catholic University of Korea Uijeongbu St.Marys Hostpial, Uijeongbu-si

14068

RECRUITING

Hallym University Medical Center, Anyang-si

47392

RECRUITING

Inje University Busan Paik Hospital, Busan

01757

RECRUITING

Inje University Sanggye Paik Hospital, Seoul

02447

RECRUITING

KyungHee University Medical Center, Seoul

03722

RECRUITING

Severance Hospital, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

06591

RECRUITING

The Catholic University of Korea, Seoul

08308

RECRUITING

Korea University Guro Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

The Catholic University of Korea

OTHER

collaborator

Kyunghee University Medical Center

OTHER

collaborator

Korea University Guro Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Inje University

OTHER

collaborator

Hallym University Medical Center

OTHER

collaborator

The Catholic University of Korea Uijeongbu St.Marys Hostpial

UNKNOWN

lead

Glaceum

INDUSTRY

NCT06329141 - A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients | Biotech Hunter | Biotech Hunter